Erratum: Crizotinib Treatment for Lorlatinib-resistant MET-amplified EML4-ALK-fusion Positive Advanced Lung Adenocarcinoma: A Case Report

Erratum: Crizotinib Treatment for Lorlatinib-resistant MET-amplified EML4-ALK-fusion Positive Advanced Lung Adenocarcinoma: A Case Report

Saved in:

Bibliographic Details
Main Author:	Editorial Office of Chinese Journal of Lung Cancer
Format:	Article
Language:	zho
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2025-03-01
Series:	Chinese Journal of Lung Cancer
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2025.103.01
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Crizotinib Treatment for Lorlatinib-resistant MET-amplified EML4-ALK-fusion Positive Advanced Lung Adenocarcinoma: A Case Report
by: Xinyi WANG, et al.
Published: (2024-12-01)

Erratum: Establishment of Human Lung Adenocarcinoma Radioresistant Cell Lines and the Mechanism of Radioresistance
by: Editorial Office of Chinese Journal of Lung Cancer
Published: (2024-10-01)

EML4‐ALK‐Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review
by: Qiongqian Li, et al.
Published: (2025-01-01)

Novel PLEC-EML4-ALK Double Fusion Underlying Crizotinib Resistance in a Metastatic Inflammatory Myofibroblastic Tumor: A Case Report
by: Alessandra Maleddu, MD, et al.
Published: (2025-05-01)

The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma
by: Didik S. Heriyanto, et al.
Published: (2020-01-01)

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient
by: Kaili Huang, et al.
Published: (2025-04-01)

A novel double fusion of EML4-ALK and PLEKHA7-ALK contribute to rapid progression of lung adenocarcinoma: a case report and literature review
by: Zhongzhao Wang, et al.
Published: (2024-11-01)

Lung Adenocarcinoma Expressing an EML4‐ALK Fusion Transcript With Premature Stop Codons and Response to Alectinib: A Case Report
by: Mami Ozaki, et al.
Published: (2025-08-01)

A Case of Multiple Primary Pulmonary Neuroendocrine Carcinoma with EML4-ALK Fusion Gene Positive
by: Yin ZHANG, et al.
Published: (2025-03-01)

A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib
by: Mehmet Artaç, et al.
Published: (2018-08-01)

Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review
by: Mingyue Wang, et al.
Published: (2025-02-01)

Response to crizotinib in advanced intrahepatic cholangiocarcinoma with ZKSCAN1-MET fusion and MET amplification: case reports and literature review
by: Jian-Hui Wu, et al.
Published: (2025-06-01)

EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER
by: A. A. Paichadze, et al.
Published: (2020-03-01)

Case Report: A rare case of ALK-KIF5B gene fusion benefited from treatment with lorlatinib
by: Yuxi Luo, et al.
Published: (2025-08-01)

Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review
by: Huang Chen, et al.
Published: (2024-12-01)

Ensartinib for EML4-ALK-positive lung adenocarcinoma with comorbid mutations in TP53, EGFR, and ERBB2: a case report
by: Xiaoqing Huang, et al.
Published: (2025-02-01)

CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib
by: Yihua Huang, et al.
Published: (2025-04-01)

A case of pulmonary ALK-positive histiocytosis combined with Birt-Hogg-Dubé syndrome carrying an EML4::ALK gene fusion: a case report and literature review
by: Shuzhe Yang, et al.
Published: (2025-01-01)

Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China
by: Zhujun Chen, et al.
Published: (2025-07-01)

Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study
by: A. S. Kolbin, et al.
Published: (2023-11-01)

Case Report: A rare case of MET-amplified gastric cancer with systemic metastasis: remarkable efficacy of crizotinib and the role of precision medicine
by: Yan Shen, et al.
Published: (2025-08-01)

Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China
by: Guangming Tian, et al.
Published: (2025-05-01)

Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK.
by: Yuki Uchihara, et al.
Published: (2017-01-01)

Case Report: Severe brigatinib-induced pneumonitis in a patient with EML4–ALK+ metastatic non-small cell lung adenocarcinoma
by: Khyati Somayaji Dasika, et al.
Published: (2025-04-01)

Partial response to treatment with ALK inhibitor in a patient with SQSTM1-ALK fusion positive lung adenocarcinoma
by: Brenda Paola Rodriguez Arroyo, et al.
Published: (2024-11-01)

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
by: Athanasios R Paliouras, et al.
Published: (2020-06-01)

Lorlatinib overcomes alectinib‐induced hemolytic anemia in an ALK fusion positive non‐small‐cell lung cancer patient with severe tumor‐associated liver failure: A case report
by: Kei Kunimasa, et al.
Published: (2024-12-01)

Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis.
by: Fengzhi Zhao, et al.
Published: (2015-01-01)

An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer
by: Richard Junior Zapata Dongo, et al.
Published: (2025-06-01)

Safety of Lorlatinib in Patients with Unresectable Advanced <i>ALK</i>-Positive Non-Small-Cell Lung Cancer Previously Treated with ALK Inhibitors: A Single-Arm, Open-Label, Phase IV Study in India
by: Ullas Batra, et al.
Published: (2025-08-01)

Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France.
by: Marine Sivignon, et al.
Published: (2020-01-01)

Remarkable response to crizotinib in a patient with advanced lung adenocarcinoma harboring the MPRIP-ROS1 fusion gene: A case report
by: Yasuyuki Kishikawa, et al.
Published: (2025-01-01)

Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer
by: Josephina Sampson, et al.
Published: (2024-12-01)

Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities  (2025 Version)
by: Jun CHEN, et al.
Published: (2025-02-01)

Proteomic characterization of MET-amplified esophageal adenocarcinomas reveals enrichment of alternative splicing- and androgen signaling-related proteins
by: Bastian Grothey, et al.
Published: (2025-03-01)

Case Report: Ensartinib as a first-line treatment for SMARCA4-deficient and EML4-ALK non-small cell lung cancer
by: Yanqing Pan, et al.
Published: (2025-05-01)

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers
by: Peter Gallagher, et al.
Published: (2025-03-01)

Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK+ non‐small cell lung cancer using South Korean claims data (K‐AREAL)
by: Jeong Eun Lee, et al.
Published: (2024-07-01)

Crizotinib-Related Aseptic Abscesses in Lung Adenocarcinoma and <i>ROS1</i>-Gene Rearrangement: A Case Report
by: Thamires Oliveira-Silva, et al.
Published: (2025-01-01)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01)